-
ABOUT USThe company is a professional API manufacturer established and developed by Shijiazhuang No.4 Pharmaceutical Group to actively promote the development strategy of "API + preparation"
-
INNOVATIONDevelops fine, series, high-end API and innovative API intermediates with high added value through overcoming key technologies such as API synthesis to build variety competition advantages.
-
PRODUCTSWith the annual production 500MT of hydroxyethyl starch , 500MT of azithromycin , we are ranking in the API professional enterprises in Hebei Province and even in China .
-
RECRUITGuolong has jointly established engineering laboratories, technology research centers and other high-level innovation platforms with CAS, Zhejiang University, Tianjin University and other universities
-
CONTACTAdhering to the "love the people with quality, formed the base with integrity" business philosophy, is committed to developing the domestic high-end market and the international market.
Shijiazhuang Sihua Pharmaceutical Group’s Guangxiang Pharmaceutical has received approval for the active pharmaceutical ingredient lacosamide.
Category:
Time:2022-05-17
【概要描述】
Shijiazhuang Fourth Pharmaceutical Group has once again received good news from its research and development efforts. Recently, the active pharmaceutical ingredient—lacosamide—developed and submitted by the group’s Hebei Guangxiang Pharmaceutical Co., Ltd. has been approved by the National Medical Products Administration and can now be officially used in marketed formulations.
Shijiazhuang Fourth Pharmaceutical Group has once again received good news in its scientific research efforts. Recently, the active pharmaceutical ingredient—lacosamide—developed and submitted by Hebei Guangxiang Pharmaceutical Co., Ltd., a subsidiary of Shijiazhuang Fourth Pharmaceutical Group, has been approved by the National Medical Products Administration and can now be officially used in marketed formulations.
It is reported that lacosamide formulations are clinically primarily used for monotherapy and combination therapy of partial-onset seizures in epilepsy patients aged 4 years and older.
Previously, Shijiazhuang No.4 Pharmaceutical’s 50mg and 100mg formulations of lacosamide tablets received drug registration certificates issued by the National Medical Products Administration and are considered to have passed the evaluation of bioequivalence and therapeutic equivalence for generic drugs. The recent approval of the lacosamide active pharmaceutical ingredient will further enhance the product’s market competitiveness.
Keywords:
Recommended
Share to
SERVICE HOTLINE
Zip Code: 052165
Address: No.9 Xingye Street, Gaocheng District, Shijiazhuang City, Hebei Province
Mobile site
E code
Business license